These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23891267)

  • 1. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review.
    Charehbili A; Fontein DB; Kroep JR; Liefers GJ; Mieog JS; Nortier JW; van de Velde CJ
    Cancer Treat Rev; 2014 Feb; 40(1):86-92. PubMed ID: 23891267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term outcomes of neoadjuvant hormonal therapy versus neoadjuvant chemotherapy in breast cancer: systematic review and meta-analysis of randomized controlled trials.
    Huang L; Xu AM
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):327-334. PubMed ID: 28271747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
    Dixon JM
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
    van Dam PA; van Dam VC; Altintas S; Papadimitriou K; Rolfo C; Trinh XB
    Eur J Surg Oncol; 2016 Mar; 42(3):333-42. PubMed ID: 26776766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines.
    Madigan LI; Dinh P; Graham JD
    Breast Cancer Res; 2020 Jul; 22(1):77. PubMed ID: 32690069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant endocrine therapy for breast cancer: an overlooked option?
    Wong ZW; Ellis MJ
    Oncology (Williston Park); 2004 Apr; 18(4):411-20; discussion 421, 424, 429 passim. PubMed ID: 15134351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment.
    Li JJ; Shao ZM
    Chin Clin Oncol; 2016 Jun; 5(3):40. PubMed ID: 27164856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer.
    Kolberg HC; Aktas B; Liedtke C
    Rev Recent Clin Trials; 2017; 12(2):67-72. PubMed ID: 28155606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant endocrine therapy in primary breast cancer.
    Huober J; Krainick-Strobel U; Kurek R; Wallwiener D
    Clin Breast Cancer; 2004 Dec; 5(5):341-7. PubMed ID: 15585070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant use of endocrine therapy in breast cancer.
    Macaskill EJ; Dixon JM
    Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neoadjuvant endocrine therapy for locally advanced breast cancer].
    Viola G; Sergi D; Conti F; Lopez M
    Clin Ter; 2007; 158(5):441-52. PubMed ID: 18062352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
    Fontein DB; Charehbili A; Nortier JW; Meershoek-Klein Kranenbarg E; Kroep JR; Putter H; van Riet Y; Nieuwenhuijzen GA; de Valk B; Terwogt JM; Algie GD; Liefers GJ; Linn S; van de Velde CJ
    Eur J Cancer; 2014 Sep; 50(13):2190-200. PubMed ID: 24970786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neoadjuvant antihormonal treatment of women with breast cancer].
    Tuxen MK; Kamby C; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.
    Spring LM; Gupta A; Reynolds KL; Gadd MA; Ellisen LW; Isakoff SJ; Moy B; Bardia A
    JAMA Oncol; 2016 Nov; 2(11):1477-1486. PubMed ID: 27367583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer.
    Macaskill EJ; Renshaw L; Dixon JM
    Oncologist; 2006; 11(10):1081-8. PubMed ID: 17110627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
    Nagykálnai T
    Magy Onkol; 2008 Jun; 52(2):133-43. PubMed ID: 18640889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
    Barbie TU; Ma C; Margenthaler JA
    Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant endocrine treatment in primary breast cancer - review of literature.
    Mathew J; Asgeirsson KS; Jackson LR; Cheung KL; Robertson JF
    Breast; 2009 Dec; 18(6):339-44. PubMed ID: 19836953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.